Cancer Diagnosis and Treatment Evaluation, 2nd Edition: Editors and Contributors

Editors

Hans-Joachim Schmoll

University Clinic Halle, Halle, Germany

(Eds, 1st Edition (2009): H.J. Schmoll, L. Van't Veer, J. Vermorken, D. Schrijvers)

Contributors

Chapter 1 - Introduction

J.B. Vermorken: Department of Medical Oncology University Hospital Antwerp Antwerp, Belgium

D. Schrijvers: Department of Medical Oncology - Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium

Chapter 2 - Pathology

W.A.M. Blokx: Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands

H. van Krieken: Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands

Chapter 3 - Role of Circulating Biomarkers in Oncology

M.J. Duffy: Clinical Research Centre, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland

A. Demir: Department of Clinical Chemistry, Meander Medical Center, Amersfoort, The Netherlands

J.M.G. Bonfrer: Clinical laboratories, PUM Netherlands Senior Experts, VK Heemstede, The Netherlands

Chapter 4 - Radiological Imaging

S.J. Gwyther: Department of Medical Imaging East Surrey Hospital, Surrey, United Kingdom

C. Thorning: Department of Medical Imaging, Epsom and St Helier University Hospitals, NHS Trust, Surrey, United Kingdom

Chapter 5 - Nuclear Medicine Imaging and Therapy

G. Jerusalem: Medical Oncology, Department of Medicine, CHU Sart Tilman, Liege and Liege University, Liege, Belgium

N. Withofs: Nuclear Medicine, Nuclear Medicine and Oncological Imaging Division, Medical Physic Department CHU Sart Tilman, Liege, Belgium

Chapter 6 - Staging Procedures

B. Zakotnik: Institute of Oncology Ljubljana, Department of Medical Oncology Ljubljana, Slovenia

H.K. van Halteren: Admiraal de Ruijter Hospital, Department of Medical Oncology Medicine Goes/Vlissingen, The Netherlands

Chapter 7 - Prognostic Factors

D. Schrijvers: Department of Medical Oncology Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium

Chapter 8 - Predictive Tumour Markers

M. Ignatiadis: Medical Oncology Department J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles Brussels, Belgium

T.M. Fouad: Medical Oncology Department J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles Brussels, Belgium

C. Sotiriou: Medical Oncology Department J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles Brussels, Belgium

Chapter 9 - Factors Determining Anti-Cancer Treatment

D. Schrijvers: Department of Medical Oncology Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium

Chapter 10 - Treatment Evaluation of Activity: From Global to Personalised

S. Marreaud: EORTC, Brussels, Belgium

D. Lacombe: EORTC, Brussels, Belgium

V. Golfinopoulos: EORTC, Brussels, Belgium

Chapter 11 - Acute and Subactue Toxicity of Cancer Medical Treatments

V. Guarneri: Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, Padova, Italy

P.F. Conte: Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, Padova, Italy

Chapter 12 - Late Toxicity

S.D. Fosså: Oslo University Hospital, Radiumhospitalet, Department of Oncology, National Advisory Unit on Late Effects after Cancer Treatment, Oslo

C.E. Kiserud: Oslo University Hospital, Radiumhospitalet, Department of Oncology, National Advisory Unit on Late Effects after Cancer Treatment, Oslo

Chapter 13 - Acute and Late Effects in Radiation Oncology and Surgery

P. Meijnders: Department of Radiotherapy, Iridium Cancer Network, Antwerp, Belgium

P. Willemsen: Department of Surgery, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium

Chapter 14 - Psychological Effects of Cancer and Treatment

M.J. Schroevers: University Medical Center Groningen, Department of Health Sciences, University of Groningen, Groningen, The Netherlands

L.M. Gualthérie van Weezel: The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital Amsterdam, The Netherlands

R Sanderman: University Medical Center Groningen, Department of Health Sciences, University of Groningen, Groningen, The Netherlands

Chapter 15 – Incapacity due to Cancer and Cancer Therapy

K. Strasser-Weippl: Department of Medicine I Center for Oncology and Hematology Wilhelminen Hospital, Vienna, Austria

H. Ludwig: Department of Medicine I Center for Oncology and Hematology Wilhelminen Hospital, Vienna, Austria

Chapter 16 - Reintegration into the Workplace

B. Mrinakova: Department of Medical oncology, St. Elisabeth Cancer Institute, Bratislava, Slovakia

I. Belohorska: Slovak Medical University, Bratislava, Slovakia

Chapter 17 - Quality of Life Issues

A. Bottomley: Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

C. Coens: Quality of Life Department, European Organisation for Research and Treatment of Cancer Brussels, Belgium

H. Flechtner: Clinic for Child and Adolescent Psychiatry and Psychotherapy, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

G. Velikova: University of Leeds, St James’s Institute of Oncology, St James’s Hospital, Leeds, U.K.

Chapter 18 - Conclusion

D. Schrijvers: Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium

 

Declarations of Interest

Chapter 1: J.B. Vermorken has declared no conflicts of interest.
D. Schrijvers has declared no conflicts of interest.

Chapter 2: W.A.M. Blokx has declared no conflicts of interest.
H. van Krieken has declared no conflicts of interest.

Chapter 3: M.J. Duffy has declared no conflicts of interest.
A. Demir has declared no conflicts of interest.
J.M.G. Bonfrer has declared no conflicts of interest.

Chapter 4: S.J. Gwyther has declared no conflicts of interest.
C. Thorning has declared no conflicts of interest.

Chapter 5: G. Jerusalem has declared no conflicts of interest.
N. Withofs has declared no conflicts of interest.

Chapter 6: B. Zakotnik has declared no conflicts of interest.
H.K. van Halteren has declared no conflicts of interest.

Chapter 7: D. Schrijvers has declared no conflicts of interest.

Chapter 8: M. Ignatiadis is primary investigator of the treat CTC trial that receives support from Roche and Janssen Diagnostics. Dr Ignatiadis also received honorarium from Novartis.
T.M. Fouad has declared no conflicts of interest.
C. Sotiriou has declared no conflicts of interest.

Chapter 9: D. Schrijvers has declared no conflicts of interest.

Chapter 10: S. Marreaud has declared no conflicts of interest.
D. Lacombe has declared no conflicts of interest.
V. Golfinopoulos has declared no conflicts of interest.

Chapter 11: V. Guarneri has declared no conflicts of interest.
P.F. Conte has declared no conflicts of interest.

Chapter 12: S.D. Fosså has declared no conflicts of interest.
C.E. Kiserud has declared no conflicts of interest.

Chapter 13: P. Meijnders has declared no conflicts of interest.
P. Wellemsen has declared no conflicts of interest.

Chapter 14: M.J. Schroevers has declared no conflicts of interest.
L.M. Gualthérie van Weezel has declared no conflicts of interest.
R Sanderman has declared no conflicts of interest.

Chapter 15: K. Strasser-Weippl has declared no conflicts of interest.
H. Ludwig has declared institutional research funding from Takeda and having received honorari and speaker engagements from Onyx, Bristol Myers Squibb, Celgene, Janssen Cilag, and Amgen.

Chapter 16: B. Mrinakova has declared no conflicts of interest.
I. Belohorska has declared no conflicts of interest.

Chapter 17: A. Bottomley has declared no conflicts of interest.
C. Coens has declared no conflicts of interest.
H. Flechtner has declared no conflicts of interest.
G. Velikova has declared being the past Chair of the EORTC Quality of Life Group (no financial interests).

Chapter 18: D. Schrijvers has declared no conflicts of interest.

« Previous Page

Last update: 24 November 2015